Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide in Early-Stage AR+ Triple-Negative Breast Cancer
NCT07016399Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in triple-negative breast cancer (TNBC). Started Sep 2025; status: recruiting.
02
Drugs
darolutamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07016399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07016399.